Selexipag for the treatment of pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Selexipag for the treatment of pulmonary arterial hypertension

Published:2016-08-02 Issue:13 Volume:17 Page:1825-1834
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Richter Manuel Jonas¹²,Gall Henning¹,Grimminger Jan¹³,Grimminger Friedrich¹,Ghofrani Hossein-Ardeschir¹²⁴

Affiliation:

1. Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, member of the German Center of Lung Research (DZL)

2. Department of Pneumology, Kerckhoff Heart and Thoracic Center, Bad Nauheim, Germany

3. Center for Pulmonary Hypertension, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

4. Department of Medicine, Imperial College London, London, UK

Funder

Justus Liebig Universität Gießen

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2016.1215429

Reference94 articles.

1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2. The molecular targets of approved treatments for pulmonary arterial hypertension

3. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

4. Prostanoid Receptors: Structures, Properties, and Functions

5. Prostanoid signal transduction and gene expression in the endothelium: Role in cardiovascular diseases

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new HPLC method for selexipag analysis in pharmaceutical formulation and bulk form;European Journal of Life Sciences;2023-08-28

2. Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations;Respiratory Medicine;2018-10

3. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review;Expert Review of Respiratory Medicine;2017-04-24